DiMasi JA - Search Results

1

Cost of innovation in the pharmaceutical industry.

DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. DiMasi JA, et al. J Health Econ. 1991 Jul;10(2):107-42. doi: 10.1016/0167-6296(91)90001-4. J Health Econ. 1991. PMID: 10113009

2

New drug development in the United States from 1963 to 1990.

DiMasi JA, Bryant NR, Lasagna L. DiMasi JA, et al. Clin Pharmacol Ther. 1991 Nov;50(5 Pt 1):471-86. doi: 10.1038/clpt.1991.172. Clin Pharmacol Ther. 1991. PMID: 1934860 No abstract available.

3

New indications for already-approved drugs: an analysis of regulatory review times.

DiMasi JA, Kaitin KI, Fernandez-Carol C, Lasagna L. DiMasi JA, et al. J Clin Pharmacol. 1991 Mar;31(3):205-15. doi: 10.1002/j.1552-4604.1991.tb04963.x. J Clin Pharmacol. 1991. PMID: 2019661

4

Success rates for new drugs entering clinical testing in the United States.

DiMasi JA. DiMasi JA. Clin Pharmacol Ther. 1995 Jul;58(1):1-14. doi: 10.1016/0009-9236(95)90066-7. Clin Pharmacol Ther. 1995. PMID: 7628176 No abstract available.

5

Risks, regulation, and rewards in new drug development in the United States.

DiMasi JA. DiMasi JA. Regul Toxicol Pharmacol. 1994 Apr;19(2):228-35. doi: 10.1006/rtph.1994.1021. Regul Toxicol Pharmacol. 1994. PMID: 8041920 Review. No abstract available.

6

Rising research and development costs for new drugs in a cost containment environment.

DiMasi JA. DiMasi JA. Pharmacoeconomics. 1992;1(Suppl 1):13-20. doi: 10.2165/00019053-199200011-00006. Pharmacoeconomics. 1992. PMID: 10146926

7

Research and development costs for new drugs by therapeutic category. A study of the US pharmaceutical industry.

DiMasi JA, Hansen RW, Grabowski HG, Lasagna L. DiMasi JA, et al. Pharmacoeconomics. 1995 Feb;7(2):152-69. doi: 10.2165/00019053-199507020-00007. Pharmacoeconomics. 1995. PMID: 10155302

8

New drug development in the United States from 1963 to 1999.

Dimasi JA. Dimasi JA. Clin Pharmacol Ther. 2001 May;69(5):286-96. doi: 10.1067/mcp.2001.115132. Clin Pharmacol Ther. 2001. PMID: 11371996 No abstract available.

9

Risks in new drug development: approval success rates for investigational drugs.

Dimasi JA. Dimasi JA. Clin Pharmacol Ther. 2001 May;69(5):297-307. doi: 10.1067/mcp.2001.115446. Clin Pharmacol Ther. 2001. PMID: 11371997 No abstract available.

10

Emerging role of pharmacoeconomics in the research and development decision-making process.

DiMasi JA, Caglarcan E, Wood-Armany M. DiMasi JA, et al. Pharmacoeconomics. 2001;19(7):753-66. doi: 10.2165/00019053-200119070-00004. Pharmacoeconomics. 2001. PMID: 11548911

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results